Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain

Pharmacol Ther. 2023 Jan:241:108327. doi: 10.1016/j.pharmthera.2022.108327. Epub 2022 Dec 5.

Abstract

The composition of intestinal microbiota is influenced by a number of factors, including medications, which may have a substantial impact on host physiology. Nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics are among those widely used medications that have been shown to alter microbiota composition in both animals and humans. Although much effort has been devoted to identify microbiota signatures associated with these medications, much less is known about the underlying mechanisms. Mucosal inflammation, changes in intestinal motility, luminal pH and bile acid metabolism, or direct drug-induced inhibitory effect on bacterial growth are all potential contributors to NSAID- and opioid-induced dysbiosis, however, only a few studies have addressed directly these issues. In addition, there is a notable overlap between the microbiota signatures of these drugs and certain diseases in which they are used, such as spondyloarthritis (SpA), rheumatoid arthritis (RA) and neuropathic pain associated with type 2 diabetes (T2D). The aims of the present review are threefold. First, we aim to provide a comprehensive up-to-date summary on the bacterial alterations caused by NSAIDs and opioids. Second, we critically review the available data on the possible underlying mechanisms of dysbiosis. Third, we review the current knowledge on gut dysbiosis associated with SpA, RA and neuropathic pain in T2D, and highlight the similarities between them and those caused by NSAIDs and opioids. We posit that drug-induced dysbiosis may contribute to the persistence of these diseases, and may potentially limit the therapeutic effect of these medications by long-term use. In this context, we will review the available literature data on the effect of probiotic supplementation and fecal microbiota transplantation on the therapeutic efficacy of NSAIDs and opioids in these diseases.

Keywords: Microbiota; Neuropathic pain; Nonsteroidal anti-inflammatory drugs (NSAIDs); Opioids; Rheumatoid arthritis; Spondyloarthritis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Arthritis, Rheumatoid* / drug therapy
  • Diabetes Mellitus, Type 2* / drug therapy
  • Dysbiosis / drug therapy
  • Dysbiosis / microbiology
  • Gastrointestinal Microbiome*
  • Humans
  • Inflammation / drug therapy
  • Neuralgia* / drug therapy

Substances

  • Analgesics, Opioid
  • Anti-Inflammatory Agents, Non-Steroidal